www.astro.org
Abstract # 2841 Does IMRT Offer Clinically Meaningful Advantages in the Adjuvant Management of Gastric Cancer?

Presenter: Alani, Shlomo

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos


Conclusions:
IMRT offers marginal benefits in the adjuvant treatment of gastric cancer and should only be offered to the small subset of patients with risk factors for kidney disease or pre‐existing nephropathy.

Author Disclosure: S. Alani, None; V. Soyfer, None; N. Shtraus, None; D. Schifter, None; B. W. Corn, None.